Recipharm starts new supply contract and completes facility purchase

Published: 4-Dec-2017
Manufacturing Regulatory Estates & Facilities

Recipharm commenced the supply of commercial products to Roche and completed the acquisition of the manufacturing facility located in Leganés, Spain


Recipharm is a contract development and manufacturing organisation (CDMO) in the pharmaceutical industry. It offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development.

Thomas Eldered, CEO of Recipharm, said: “We are continuing to gain momentum in the CDMO market and this latest agreement is another demonstration of this.”

“I welcome our new colleagues in Spain and look forward to providing Roche with first-class CDMO services.”

  • Companies:
  • Recipharm
See more

You may also like

Training & Education

Women in pharma: the battle against mansplaining continues

Read more
Prejudice in the workplace is an affliction suffered by many, but how can the industry be free from this nasty virus?

Trending Articles

  1. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact they’re having on the pharmaceutical industry
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  3. ISPE announces 2024 Facility of the Year Awards category winners The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
  4. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Training & Education

Women in pharma: the battle against mansplaining continues

Prejudice in the workplace is an affliction suffered by many, but how can the industry be free from this nasty virus?
Manufacturing

Recipharm, Medspray and Resyca enter into license agreement to develop nasally-delivered soft mist drug products

Recipharm, Medspray and Resyca have entered an exclusive collaboration and licensing agreement to develop soft mist nasal delivery devices for single and combination drug products.
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Recipharm’s analytical lab brings testing capabilities to global markets

Fully cGMP/cGLP compliant, the 5,000 sqft lab will expand Recipharm’s existing analytical capabilities and provide support for biotech and pharma customers
Manufacturing

BES completes $4.8m refurb for Recipharm

The 4000 sqm facility, located in King’s Lynn, has seen an extensive redesign and refurbishment
Manufacturing

Recipharm extends commercial manufacturing for RedHill’s drug

Talicia is eligible for eight years of US market exclusivity under QIDP designation and its patent protection extends at least until 2034
Manufacturing

Recipharm expands services for pMDI propellants

The company's device development team recently completed a three-year Innovate UK (IUK) knowledge transfer partnership research programme with UK universities
Subscribe now